INT2241

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1979
Last Reported 2011
Negated 1
Speculated 2
Reported most in Body
Documents 56
Total Number 59
Disease Relevance 29.32
Pain Relevance 8.83

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (CEL) extracellular space (CEL) small molecule metabolic process (CEL)
extracellular region (CEL) lipid metabolic process (CEL) cytoplasm (CEL)
Anatomy Link Frequency
endothelial cell 3
B cell 3
T-cell 3
NKC 2
ganglion cell 1
CEL (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 16 100.00 Very High Very High Very High
lidocaine 12 100.00 Very High Very High Very High
cytokine 61 99.66 Very High Very High Very High
anesthesia 29 99.52 Very High Very High Very High
rheumatoid arthritis 37 99.32 Very High Very High Very High
GABAergic 3 99.24 Very High Very High Very High
Inflammation 93 99.08 Very High Very High Very High
cINOD 16 99.04 Very High Very High Very High
Bioavailability 135 98.98 Very High Very High Very High
Parenteral administration 22 98.60 Very High Very High Very High
Disease Link Frequency Relevance Heat
Familial Adenomatous Polyposis 12 100.00 Very High Very High Very High
Colon Cancer 4 100.00 Very High Very High Very High
Ganglion Cysts 15 99.98 Very High Very High Very High
Desmoid Disease 9 99.96 Very High Very High Very High
Apoptosis 176 99.84 Very High Very High Very High
Hemolytic Anemia 5 99.76 Very High Very High Very High
Rheumatoid Arthritis 37 99.32 Very High Very High Very High
Coagulation Disorder 4 99.24 Very High Very High Very High
Hepatic Encephalopathy 1 99.24 Very High Very High Very High
Aging 19 99.16 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
It effectively inhibits or inactivates numerous serine hydrolases, including CEase.
Negative_regulation (inactivates) of CEase
1) Confidence 0.58 Published 2004 Journal BMC Pharmacol Section Body Doc Link PMC406500 Disease Relevance 0.16 Pain Relevance 0.10
Inhibition of CEase is very sensitive to the length of the tether.
Negative_regulation (Inhibition) of CEase
2) Confidence 0.58 Published 2004 Journal BMC Pharmacol Section Body Doc Link PMC406500 Disease Relevance 0.14 Pain Relevance 0.03
Compound 1 is a potent inhibitor of CEase (Kd = 25 nanomolar) and is highly selective for CEase compared to other serine hydrolases such as chymotrypsin [10].
Negative_regulation (inhibitor) of CEase
3) Confidence 0.58 Published 2004 Journal BMC Pharmacol Section Body Doc Link PMC406500 Disease Relevance 0.09 Pain Relevance 0.03
A number of different types of inhibitors of cholesterol esterase have been developed
Negative_regulation (inhibitors) of cholesterol esterase
4) Confidence 0.58 Published 2004 Journal BMC Pharmacol Section Body Doc Link PMC406500 Disease Relevance 0.09 Pain Relevance 0
However, despite its lack of selectivity, compound 2 did provide the opportunity to demonstrate in an animal study that inhibition of CEase is a new approach to the treatment of hypercholesterolemia
Negative_regulation (inhibition) of CEase associated with hyperlipidemia
5) Confidence 0.58 Published 2004 Journal BMC Pharmacol Section Body Doc Link PMC406500 Disease Relevance 0.16 Pain Relevance 0.07
Inhibitors of CEase may provide a method to limit the bioavailability of dietary cholesterol derived from cholesterol esters and may also limit the absorption of free cholesterol.
Negative_regulation (Inhibitors) of CEase associated with disorder of lipid metabolism and bioavailability
6) Confidence 0.58 Published 2004 Journal BMC Pharmacol Section Body Doc Link PMC406500 Disease Relevance 0.49 Pain Relevance 0.25
It is noteworthy that the lipid-lowering effect of WAY-121,898, a novel carbamate inhibitor of CEase, was observed both by oral and by parenteral administration of the drug [17].
Negative_regulation (inhibitor) of CEase associated with parenteral administration
7) Confidence 0.58 Published 2004 Journal BMC Pharmacol Section Body Doc Link PMC406500 Disease Relevance 0.21 Pain Relevance 0.08
[Anesthesia for a patient with red cell aldolase deficiency].
Negative_regulation (deficiency) of cell associated with anesthesia
8) Confidence 0.57 Published 1993 Journal Masui Section Title Doc Link 8515555 Disease Relevance 0.34 Pain Relevance 0.40
CONCLUSIONS: Various drugs with a triptan-like chemical structure interact with cellular components of the innate immune system, resulting in an apparent indirect inhibition of NKC activity and direct inhibition of neutrophils pMMP-9 secretion.
Negative_regulation (inhibition) of NKC in immune system
9) Confidence 0.57 Published 2008 Journal Headache Section Body Doc Link 18479418 Disease Relevance 0 Pain Relevance 0
Coagulopathy in these patients may be a result of reduced vascular endothelial cell cyclooxygenase activity secondary to increased levels of unbound nonsteroidal anti-inflammatory drug.
Negative_regulation (reduced) of cell in endothelial cell associated with coagulation disorder, inflammation and cinod
10) Confidence 0.57 Published 1983 Journal J. Pediatr. Section Abstract Doc Link 6644421 Disease Relevance 1.03 Pain Relevance 0.36
Both enhanced and reduced NK activity have been reported in different in vivo and in vitro studies.
Negative_regulation (reduced) of NK
11) Confidence 0.57 Published 1994 Journal Isr. J. Med. Sci. Section Abstract Doc Link 8088979 Disease Relevance 0 Pain Relevance 0.65
The accumulation of arachidonic acid in the medium after steroid treatment was associated with a significant inhibition of cell acyltransferase activity, suggesting that steroids may also act upon arachidonic acid metabolism at sites other than those of phospholipase activity.
Negative_regulation (inhibition) of cell
12) Confidence 0.57 Published 1986 Journal Biochim. Biophys. Acta Section Abstract Doc Link 3087432 Disease Relevance 0.16 Pain Relevance 0.24
Six months after intraocular injections and EAE sensitization, combination therapy with ECSOD and catalase decreased RGC loss by 29%, optic nerve demyelination by 36%, axonal loss by 44%, and cellular infiltration by 34% compared with the contralateral control eyes inoculated with AAV-GFP.
Negative_regulation (loss) of RGC in optic nerve
13) Confidence 0.57 Published 2007 Journal Invest. Ophthalmol. Vis. Sci. Section Body Doc Link 18055782 Disease Relevance 0.11 Pain Relevance 0
Inhibition of cytolysis in vitro was not mediated through an alteration of T-cell subsets or inhibition of T-cell soluble factors (interleukin 2).
Negative_regulation (inhibition) of cell in T-cell
14) Confidence 0.57 Published 1986 Journal Exp. Neurol. Section Abstract Doc Link 3485536 Disease Relevance 0.17 Pain Relevance 0.55
Numerous types of chemicals have been studied as either mechanism-based or reversible inhibitors of CEase, including boronic and borinic acids, arylhaloketones, aryl phosphates and phosphonates, and aryl and cholesteryl carbamates [30,31].
Negative_regulation (inhibitors) of CEase
15) Confidence 0.43 Published 2004 Journal BMC Pharmacol Section Body Doc Link PMC406500 Disease Relevance 0.08 Pain Relevance 0.03
Inhibitor 1 was shown to be a reversible inhibitor of CEase [10].


Negative_regulation (inhibitor) of CEase
16) Confidence 0.43 Published 2004 Journal BMC Pharmacol Section Body Doc Link PMC406500 Disease Relevance 0.30 Pain Relevance 0.05
The acceleration disappeared when CEase was inactivated, and the acceleration in cholesterol uptake by these cells in response to CEase occurred only when the micelles contained lecithin.
Negative_regulation (inactivated) of CEase
17) Confidence 0.43 Published 2004 Journal BMC Pharmacol Section Body Doc Link PMC406500 Disease Relevance 0 Pain Relevance 0.10
Therefore, compound 1 can now be considered the prototype for development of selective inhibitors of CEase.
Negative_regulation (inhibitors) of CEase
18) Confidence 0.43 Published 2004 Journal BMC Pharmacol Section Body Doc Link PMC406500 Disease Relevance 0.08 Pain Relevance 0
Inhibitors of cholesterol esterase are anticipated to limit the absorption of dietary cholesterol.


Negative_regulation (Inhibitors) of cholesterol esterase associated with disorder of lipid metabolism
19) Confidence 0.43 Published 2004 Journal BMC Pharmacol Section Abstract Doc Link PMC406500 Disease Relevance 0.19 Pain Relevance 0.05
Recently, the feasibility of limiting the bioavailability of cholesterol derived from cholesterol esters by inhibiting CEase was reported by Bailey, Gallo and coworkers.
Negative_regulation (inhibiting) of CEase associated with bioavailability
20) Confidence 0.43 Published 2004 Journal BMC Pharmacol Section Body Doc Link PMC406500 Disease Relevance 0.14 Pain Relevance 0.17

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox